Stem Cell Transplantation in Hodgkin Lymphoma

作者：Reddy Nishitha M; Perales Miguel Angel^*

来源：Hematology-Oncology Clinics of North America, 2014, 28(6): 1097-+.

DOI：10.1016/j.hoc.2014.08.011

• Hodgkin lymphoma
• Stem cell transplantation
• Brentuximab-vedotin
• Donor-lymphocyte infusion

Patients with Hodgkin lymphoma (HL) who relapse following effective front-line therapy are offered salvage second-line chemotherapy regimens followed by high-dose therapy and autologous stem cell transplantation (HDT/ASCT). Randomized studies comparing HDT/ASCT with conventional chemotherapy in patients with relapsed refractory HL have shown significant improvement in progression-free survival and freedom from treatment failure but were not powered to show improvements in overall survival. For patients who relapse after salvage HDT/ASCT, novel therapies exist as a bridge to allogeneic SOT. In this article, we review indications and results of autologous and allogeneic SOT in HL.

• 出版日期2014-12